Figure 6. Cooperative anticancer effect of proteasome inhibitor Bortezomib and CpdA in transformed lymphoid cells. CEM-shEV, CEM-shGR, NCEB-shEV and NCEB-shGR cells were incubated with solvent, CpdA, BZ or CpdA/BZ for 48 h. (A) Cell growth was evaluated by cell counting. (B and C) Apoptosis in CEM and NCEB cells was analyzed by western blot analysis of PARP cleavage (B) and by flow cytometry using propidium iodide staining (C). The number of apoptotic cells was calculated as percentage to all cells in sample (C andD). Number of cells in S-phase was determined by flow cytometry using propidium iodide staining. Statistically significant difference (*p < 0.05; ** p < 0.01) between treated and control cells; #, statistically significant difference (p < 0.05) between CpdA and BZ+CpdA.